Alzubi, Jamal, Dettmer-Monaco, Viviane, Kuehle, Johannes, Thorausch, Niko, Seidl, Maximilian, Taromi, Sanaz, Schamel, Wolfgang, Zeiser, Robert, Abken, Hinrich, Cathomen, Toni ORCID: 0000-0002-7757-4630 and Wolf, Philipp (2020). PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. Mol. Ther.-Oncolytics, 18. S. 226 - 236. CAMBRIDGE: CELL PRESS. ISSN 2372-7705

Full text not available from this repository.

Abstract

While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far. To improve the efficacy of CAR T cells targeting prostate carcinoma, we designed a novel CAR that recognizes a new epitope in the prostate-specific membrane antigen (PSMA) and established novel paradigms to apply CAR T cells in a preclinical prostate cancer model. In vitro characterization of the D7 single-chain antibody fragment-derived anti-PSMA CAR confirmed that the choice of the co-stimulatory domain is a major determinant of CART cell activation, differentiation, and exhaustion. In vivo, focal injections of the PSMA CAR T cells eradicated established human prostate cancer xenografts in a preclinical mouse model. Moreover, systemic intravenous CAR T cell application significantly inhibited tumor growth in combination with non-ablative low-dose docetaxel chemotherapy, while docetaxel or CAR T cell application alone was not effective. In conclusion, the focal application of D7-derived CAR T cells and their combination with chemotherapy represent promising immunotherapeutic avenues to treat local and advanced prostate cancer in the clinic.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Alzubi, JamalUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dettmer-Monaco, VivianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuehle, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thorausch, NikoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seidl, MaximilianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Taromi, SanazUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schamel, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zeiser, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Abken, HinrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cathomen, ToniUNSPECIFIEDorcid.org/0000-0002-7757-4630UNSPECIFIED
Wolf, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-318289
DOI: 10.1016/j.omto.2020.06.014
Journal or Publication Title: Mol. Ther.-Oncolytics
Volume: 18
Page Range: S. 226 - 236
Date: 2020
Publisher: CELL PRESS
Place of Publication: CAMBRIDGE
ISSN: 2372-7705
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHIMERIC ANTIGEN RECEPTORS; MEMBRANE ANTIGEN; IN-VITRO; EXPRESSION; GENOME; TARGET; IMMUNOTOXIN; ACTIVATION; DIAGNOSIS; THERAPYMultiple languages
Oncology; Medicine, Research & ExperimentalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31828

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item